Copley Scientific Launches New Products for MDI Testing in Line with the New USP Monograph
![](/46/pdcnewsitem/03/29/87/sjab3QnnMVrI55G.jpg)
Copley Scientific has launched two new products to enable testing in accordance with methods described in a new US Pharmacopoeia (USP) monograph relating to metered dose inhalers (MDIs). The USP monograph, <1602>, which is currently in draft form, addresses the testing of MDIs with spacers and valved holding chambers (VHCs) — devices that make MDIs more suitable for paediatric patients and those with poor co-ordination. The recently launched BAC 2000 breath actuated controller and BRS 1100 breathing simulator, in combination, support closely controlled testing under the representative conditions for neonate, infant, child and/or adult patients outlined in the monograph.
Inexpensive and efficient, MDIs are a popular choice for the delivery of therapeutics for pulmonary conditions. However, the co-ordination required to synchronise operation of an MDI with inhalation inhibits their use by certain patient groups, especially paediatrics. Spacers or VHC s address this issue by introducing a chamber containing dead volume between the MDI and the inhaling patient. The MDI is fired into the spacer or VHC and the patient then inhales freely to draw the drug into the lungs.
The new monograph recognises that the breathing profile of the patient affects their ability to draw the therapeutic aerosol into the lungs, from the spacer or VHC. In addition it highlights the potential variability in drug delivery efficiency arising from the introduction of a time delay between actuation of the MDI and inhalation. New test conditions are outlined, designed to capture the ‘as inhaled’ characteristics of the dose, under representative conditions.
The BAC 2000 is a timer controlled two way solenoid valve. It provides near instantaneous starting and stopping of the air flow during testing and has both delay and inhaled time functions. When testing MDIs in line with the new monograph the delay feature allows sampling of the aerosol from the spacer or VHC to start a defined time after actuation of the MDI. The BAC 2000 can also be useful for controlling the duration for which nebuliser sampling is conducted and for actuating breath-actuated MDIs during testing. It can be used for both dose uniformity testing and for aerodynamic particle size measurement by cascade impaction, where appropriate.
The BRS 1100 is a simple, microprocessor controlled breathing simulator designed to generate the breathing profiles specified by USP and Ph.Eur. for dose uniformity testing of nebulisers and, in the case of the new draft USP monograph, for MDIs with spacers and VHCs. Neonate, infant, child and adult profiles can all be precisely generated by varying tidal volume, frequency, duration and inhalation/exhalation ratio. Starting the breathing cycle at the point of inhalation or exhalation can also be controlled as required for the testing of MDIs with spacers and VHCs, when comparing fully co-ordinated and unco-ordinated use.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance